- Company name
- West Pharmaceutical Services
- Sector
- Injectable drug delivery systems and components
- About
- West Pharmaceutical Services, Inc. (West) makes containment and delivery products for injectable medicines. It is based in Exton, Pennsylvania. Its Proprietary Products segment makes high-value components such as elastomer stoppers and seals, high-value delivery devices such as the Daikyo Crystal Zenith systems, and standard products. Its West Vantage segment designs, makes and assembles complex devices for pharmaceutical, diagnostic and medical device customers. West sells mostly to pharmaceutical and biotech companies and contract manufacturers. In 2025, net sales were $3.07 billion. It has over 10,000 team members at 50 sites, including 26 factories, and holds 49% of Daikyo Seiko, its partner in Japan. Michel Lagarde became President and Chief Executive Officer on August 31, 2026. West files 10-K and 10-Q reports with the SEC, and its common stock trades on the New York Stock Exchange in US dollars.
- Thesis
- The price of West depends on whether high-value components can keep growing at a double-digit rate while margins rise. In Q3 of 2026, net sales rose 8.7% to $874.5 million, organic growth was 11.9% and adjusted EPS rose 35.7% to $2.66. High-value components, which are 53% of sales, grew 19.7%, led by demand for biologic and GLP-1 medicines. The company raised its guidance for 2026 to adjusted EPS of $9.38 to $9.48. The market has to weigh this against a cyber attack in May 2026 that stopped operations for some time, a change of chief executive and a weak West Vantage segment, where sales fell 7.3%. A gain of $55.7 million from the sale of the SmartDose 3.5mL system also helped reported results in Q3. For the price to hold or rise, three things must be true. Orders for high-value components must keep growing at a double-digit rate as customers launch more biologic and GLP-1 products. The adjusted operating margin must keep rising from 23.1% in the first nine months of 2026. The new chief executive must keep the plan without more operating problems. The next tests are the Q4 report with the first view of 2027, expected in February 2027, and the Q1 report in April 2027.
- Risks
- Growth depends on a few kinds of customer demand. Sales of high-value components rose because of biologic and GLP-1 medicines. A slowdown in launches or in orders would cut growth and the margin.
The cyber attack of May 2026 can still cost money. The company said that it had one-time professional fees for it, and the investigation of the data that was taken was still open at the time of its first report.
A new chief executive started on August 31, 2026. Changes of plan or of managers can disturb a business that is growing fast.
The West Vantage segment is weak. Its sales fell 7.3% in Q3, and its operating profit was $15.5 million, down from $22.3 million.
West is the licensee of the Daikyo Crystal Zenith technology and holds 49% of Daikyo. A change in the agreements with Daikyo would hurt its delivery devices.
- Balance sheet
- Cash: $464M
Debt: $203M
Net cash: $261M
Undrawn credit line: $498M
At September 30, 2026, West had cash of $464.1 million, down from $791.3 million at December 31, 2025. Total debt was $202.9 million. It had no borrowings under its revolving credit facility of $500.0 million, of which $497.7 million was available after letters of credit. On October 26, 2026, it replaced its credit facilities with a new agreement that has a revolving facility of $750 million and a term loan of $200 million, due on October 26, 2031. Total equity was $2,968.2 million, down from $3,176.0 million at the end of 2025, because West bought back $685.3 million of stock in the first nine months. Operating cash flow was $403 million and capital spending was $125 million in that period. The company expects capital spending of $215 million to $220 million for 2026.
As of Sep 30, 2026.
- Checkpoints
- Feb 11, 2027 (estimate): Q4 2026 results and the first view of 2027. Pending. Watch: High-value components keep growing at a double-digit rate and the adjusted operating margin rises, and this passes; slower growth or a lower margin fails.
Apr 2027 (estimate): Q1 2027 results. Pending. Watch: Organic growth stays above 10% under the new chief executive with no new operating problem, and this passes; a clear slowdown fails.
Jul 2027 (estimate): Q2 2027 results: first-half margin. Pending. Watch: The adjusted operating margin for the first half of 2027 is above the 23.1% of the first nine months of 2026, and this passes; a lower margin fails.
- Recent events
- Oct 29, 2026: West reported Q3 2026 results. Net sales rose 8.7% to $874.5 million, and adjusted EPS rose 35.7% to $2.66. The company raised its guidance for 2026 to net sales of $3.41 billion to $3.42 billion and adjusted EPS of $9.38 to $9.48. It declared a Q4 dividend of $0.26 per share, up 18%.
Oct 29, 2026: West bought back $231 million of stock in Q3 and $685 million in the first nine months. About $314.7 million remains under its authorization of $1.0 billion. Its cash fell to $464.1 million from $791.3 million at the end of 2025.
Oct 26, 2026: West signed a new senior unsecured credit agreement with Bank of America as agent. It has a revolving facility of $750 million and a term loan of $200 million, and it matures on October 26, 2031.
Jul 14, 2026: West and Daikyo Seiko signed an amended and restated technology exchange and cross-license agreement and two distributor agreements. The terms are much like those of the agreements of 2017. West holds 49% of Daikyo.
Jul 1, 2026: West completed the sale of the manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and its factories to AbbVie for $126.9 million in cash. It booked a pre-tax gain of $55.7 million and expects savings of $15 million to $20 million a year.
Jun 1, 2026: West named Michel Lagarde, who was Chief Operating Officer of Thermo Fisher Scientific, as President and Chief Executive Officer from August 31, 2026. Eric Green, who told the board in March that he would retire, leaves the roles on that date.
May 11, 2026: West said that it found a material cyber attack on May 4, 2026. Some data was taken and some systems were encrypted, and the company took systems offline around the world. Core systems were back and shipping and making had restarted at some sites, but the full cost was not yet known.